Literature DB >> 27488866

Optimal control therapy and vaccination for special HIV-1 model with delay.

Elham Shamsara1, Jamal Shamsara2, Zahra Afsharnezhad3.   

Abstract

In this paper, we consider a four dimensional model of the human immunodeficiency virus-1 (HIV-1) with delay, which is an extension of some three dimensional models. We approach the treatment problem by adding two controllers to the system for inhibiting viral production. The optimal controller [Formula: see text] is considered for vaccine and [Formula: see text] for the drug. The Pontryagin maximum principle with delay is used to characterize these optimal controls. At the end, numerical results are presented to illustrate the optimal solutions. The validity of the model was confirmed by proper semi-quantitative simulation of some clinical data. The model was used to predict the possible beneficial effects of vaccine and anti-retroviral drug administration in HIV-1 disease.

Entities:  

Keywords:  CTL response; HIV-1 infection; Optimal control; Pontryagin maximum principle with delay

Mesh:

Year:  2016        PMID: 27488866     DOI: 10.1007/s12064-016-0234-x

Source DB:  PubMed          Journal:  Theory Biosci        ISSN: 1431-7613            Impact factor:   1.919


  14 in total

1.  Long-term CD4(+) and CD8(+) T-cell responses induced in HIV-uninfected volunteers following intradermal or intramuscular administration of an HIV-lipopeptide vaccine (ANRS VAC16).

Authors:  Odile Launay; Mathieu Surenaud; Corinne Desaint; Nadine Ben Hamouda; Gilles Pialoux; Bénédicte Bonnet; Isabelle Poizot-Martin; Gustavo Gonzales; Lise Cuzin; Isabelle Bourgault-Villada; Yves Lévy; Jeannine Choppin; Christine Durier
Journal:  Vaccine       Date:  2013-07-11       Impact factor: 3.641

2.  Optimal Control of a Delayed SIRS Epidemic Model with Vaccination and Treatment.

Authors:  Hassan Laarabi; Abdelhadi Abta; Khalid Hattaf
Journal:  Acta Biotheor       Date:  2015-01-13       Impact factor: 1.774

Review 3.  Modeling T cell responses to antigenic challenge.

Authors:  Dominik Wodarz
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-10-01       Impact factor: 2.745

4.  Therapeutic immunisation plus cytokine and hormone therapy improves CD4 T-cell counts, restores anti-HIV-1 responses and reduces immune activation in treated chronic HIV-1 infection.

Authors:  Anna Herasimtschuk; Jocelyn Downey; Mark Nelson; Graeme Moyle; Sundhiya Mandalia; Rein Sikut; Maarja Adojaan; Ioana Stanescu; Frances Gotch; Nesrina Imami
Journal:  Vaccine       Date:  2014-10-22       Impact factor: 3.641

Review 5.  Preserving HIV-specific T cell responses: does timing of antiretroviral therapy help?

Authors:  Bernard J C Macatangay; Charles R Rinaldo
Journal:  Curr Opin HIV AIDS       Date:  2015-01       Impact factor: 4.283

6.  Early antiretroviral therapy with raltegravir generates sustained reductions in HIV reservoirs but not lower T-cell activation levels.

Authors:  William J Hey-Cunningham; John M Murray; Ven Natarajan; Janaki Amin; Cecilia L Moore; Sean Emery; David A Cooper; John Zaunders; Anthony D Kelleher; Kersten K Koelsch
Journal:  AIDS       Date:  2015-05-15       Impact factor: 4.177

Review 7.  Antiretroviral therapy and management of HIV infection.

Authors:  Paul A Volberding; Steven G Deeks
Journal:  Lancet       Date:  2010-07-03       Impact factor: 79.321

Review 8.  A brief history of antiretroviral therapy of HIV infection: success and challenges.

Authors:  Lucia Palmisano; Stefano Vella
Journal:  Ann Ist Super Sanita       Date:  2011       Impact factor: 1.663

9.  Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy.

Authors:  Tuan Le; Edwina J Wright; Davey M Smith; Weijing He; Gabriel Catano; Jason F Okulicz; Jason A Young; Robert A Clark; Douglas D Richman; Susan J Little; Sunil K Ahuja
Journal:  N Engl J Med       Date:  2013-01-17       Impact factor: 91.245

10.  Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study.

Authors:  Asier Sáez-Cirión; Charline Bacchus; Laurent Hocqueloux; Véronique Avettand-Fenoel; Isabelle Girault; Camille Lecuroux; Valerie Potard; Pierre Versmisse; Adeline Melard; Thierry Prazuck; Benjamin Descours; Julien Guergnon; Jean-Paul Viard; Faroudy Boufassa; Olivier Lambotte; Cécile Goujard; Laurence Meyer; Dominique Costagliola; Alain Venet; Gianfranco Pancino; Brigitte Autran; Christine Rouzioux
Journal:  PLoS Pathog       Date:  2013-03-14       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.